AgingResearch.NewsJoin free

Quadruple guideline-directed medical therapy

Quadruple guideline-directed medical therapy has been studied in 5 papers since 2026: 4 observational studies in people, 1 review; 5 in the past year. The newest story, Oct 26, 2026: “Four heart failure drugs linked to fewer deaths in older adults”.

Intervention

5 papers study it6 findingsUpdated

3 new papers in 30 daysSee all 5 papers on quadruple guideline-directed medical therapy

At a glance

The findings reach people, from one lab or study. 2 independent labs in 2 countries.

“In adjusted analyses, incomplete therapy was associated with higher 30-day mortality (adjusted risk ratio 5.90; 95% confidence interval 4.05–8.58; p<0.001).”
Impact of quadruple guideline-directed medical therapy at discharge on thirty-day mortality in older adults with heart failure and reduced ejection fraction: a real-world registryESC Congress 2026 abstract2026doi:10.1093/eurheartj/ehag785.1506

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

  • 2 independent labs in 2 countries
  • Humans4

What did studies of quadruple guideline-directed medical therapy find?

3

Studies of quadruple guideline-directed medical therapy measured 3 outcomes: cardiovascular mortality, Hospitalization-associated expenditures and heart failure hospitalization.

Cardiovascular mortality

downin humans1

1 study

  1. Quadruple guideline-directed medical therapy decreases cardiovascular mortality in humans (heart failure with reduced ejection fraction).

    “produces complementary reductions in cardiovascular mortality and rehospitalization”

    Reviewheart failure with reduced ejection fraction

    The translational gap in quadruple heart failure therapy in East and Southeast Asia: Barriers and a proposed phenotype-adapted implementation model

    Journal of Clinical and Translational Research

Hospitalization-associated expenditures

downin silico1

1 study

  1. Quadruple guideline-directed medical therapy decreases hospitalization-associated expenditures in silico (full implementation vs partial GDMT, modeled from pivotal RCT effect estimates) ($9780 (95% CI, $7900-$11 660) per patient annually).

    “Full quadruple therapy implementation vs partial GDMT was projected to reduce hospitalization-associated expenditures by $9780 (95% CI, $7900-$11 660) per patient annually.”

    In silicofull implementation vs partial GDMT, modeled from pivotal RCT effect estimates1 year after discharge

    Cost Offset With Quadruple Therapy for Heart Failure

    JAMA cardiology

Heart failure hospitalization

downin silico1

1 study

  1. Quadruple guideline-directed medical therapy decreases heart failure hospitalization in silico (modeled from pivotal RCT effect estimates) (87% (95% CI, 81%-91%) relative reduction).

    “Modeled quadruple GDMT was associated with an 87% (95% CI, 81%-91%) relative reduction in HF hospitalizations”

    In silicomodeled from pivotal RCT effect estimates1 year after discharge

    Cost Offset With Quadruple Therapy for Heart Failure

    JAMA cardiology

What is quadruple guideline-directed medical therapy linked with?

3

Studies link quadruple guideline-directed medical therapy with 3 measures: 30-day all-cause readmission, mortality and Net annual cost.

30-day all-cause readmission

downin humans1

1 study

  1. Quadruple guideline-directed medical therapy is associated with 30-day all-cause readmission in humans (Heart failure admissions; discharge quadruple therapy compared with incomplete GDMT) (43% lower readmission; 31.8% vs 56.2%; ARR=24.3%, NNT=4.1).

    “Quadruple GDMT at discharge was associated with 43% lower readmission (NNT=4.1), though causality cannot be established.”

    HumansHeart failure admissions; discharge quadruple therapy compared with incomplete GDMT30 days49% femalesn = 168

    Quadruple GDMT Reduces 30-Day Heart Failure Readmission in Real-World: SGLT2i Underutilisation Drives the Implementation Gap

    AHA Scientific Sessions 2026 abstract

Mortality

downin humans1

1 study

  1. Quadruple guideline-directed medical therapy is linked with a lower risk of mortality in humans (heart failure with reduced ejection fraction) (adjusted risk ratio 5.90; 95% confidence interval 4.05–8.58; p<0.001).

    “In adjusted analyses, incomplete therapy was associated with higher 30-day mortality (adjusted risk ratio 5.90; 95% confidence interval 4.05–8.58; p<0.001).”

    Humansheart failure with reduced ejection fraction30-day

    Four heart failure drugs linked to fewer deaths in older adults

    ESC Congress 2026 abstract

Net annual cost

mixedin silico1

1 study

  1. Quadruple guideline-directed medical therapy is associated with net annual cost in silico after drug acquisition costs across regimens (from $8556 in savings to $6347 in net cost).

    “the resulting net annual cost ranged from $8556 in savings to $6347 in net cost, with most regimens yielding net savings”

    In silicoafter drug acquisition costs across regimens1 year after discharge

    Cost Offset With Quadruple Therapy for Heart Failure

    JAMA cardiology

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 1Jul 2026: 0Aug 2026: 0Sep 2026: 1Oct 2026: 2Nov 2026: 15 papers in 12 months
ESC Congress 2026 Abstract

Four heart failure drugs linked to fewer deaths in older adults

Thirty-day mortality was 2.9% among older patients discharged on all four recommended drug types, versus 19.1% among those prescribed three or fewer.Thirty-day mortality was 2.9% among older patients discharged on all four recommended drug types, versus 19.1% among those prescribed three or fewer.

Cohort · 1,868 peoplePopulations
Paper

Related